Tags

Type your tag names separated by a space and hit enter

Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma.

Abstract

OBJECTIVE

The objective of this review was to evaluate different measures of efficacy of the intraocular pressure (IOP) lowering lipid class agents bimatoprost, latanoprost and travoprost in the treatment of primary open angle glaucoma. Study arms of timolol in trials including the above mentioned lipid class drugs were also included.

METHODS

MEDLINE and EMBASE were searched for randomized clinical trials including one or more of the lipid class drugs bimatoprost, latanoprost and travoprost. The study results were pooled, and the simple, weighted IOP-lowering efficacy was compared among the lipid class drugs and timolol, where data were available. Efficacy parameters were reviewed, including mean reduction of IOP and percentage of patients achieving different levels of IOP.

RESULTS

161 articles were identified of which 42 were included in the analysis. A total of 9295 patients participated in the included trials. Based on all studies, timolol on average had a weighted mean IOP reduction of 22.2%, while latanoprost, travoprost and bimatoprost had a weighted mean IOP reduction of 26.7%, 28.7% and 30.3%, respectively. Analysis of target achievement to various IOP levels shows that bimatoprost seems more efficacious than latanoprost. The direct comparisons (head-to-head studies) also show that bimatoprost is the most efficacious treatment, however it is not conclusive whether latanoprost or travoprost is better in reducing IOP.

CONCLUSIONS

This review shows that bimatoprost seems to be the most efficacious treatment in lowering IOP. Head-to-head studies confirm this.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Allergan Europe, Pforzheimer Str. 160, D-76275 Ettlingen, Germany.

    , , ,

    Source

    Current medical research and opinion 21:11 2005 Nov pg 1875-83

    MeSH

    Adrenergic beta-Antagonists
    Adult
    Amides
    Bimatoprost
    Clinical Trials as Topic
    Cloprostenol
    Glaucoma, Open-Angle
    Humans
    Intraocular Pressure
    Latanoprost
    Lipids
    Prostaglandins F, Synthetic
    Randomized Controlled Trials as Topic
    Timolol
    Travoprost
    Treatment Outcome

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't
    Review

    Language

    eng

    PubMed ID

    16307709

    Citation

    Holmstrom, Stefan, et al. "Analytic Review of Bimatoprost, Latanoprost and Travoprost in Primary Open Angle Glaucoma." Current Medical Research and Opinion, vol. 21, no. 11, 2005, pp. 1875-83.
    Holmstrom S, Buchholz P, Walt J, et al. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Curr Med Res Opin. 2005;21(11):1875-83.
    Holmstrom, S., Buchholz, P., Walt, J., Wickstrøm, J., & Aagren, M. (2005). Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Current Medical Research and Opinion, 21(11), pp. 1875-83.
    Holmstrom S, et al. Analytic Review of Bimatoprost, Latanoprost and Travoprost in Primary Open Angle Glaucoma. Curr Med Res Opin. 2005;21(11):1875-83. PubMed PMID: 16307709.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. AU - Holmstrom,Stefan, AU - Buchholz,Patricia, AU - Walt,John, AU - Wickstrøm,Jannie, AU - Aagren,Mark, PY - 2005/11/26/pubmed PY - 2006/2/14/medline PY - 2005/11/26/entrez SP - 1875 EP - 83 JF - Current medical research and opinion JO - Curr Med Res Opin VL - 21 IS - 11 N2 - OBJECTIVE: The objective of this review was to evaluate different measures of efficacy of the intraocular pressure (IOP) lowering lipid class agents bimatoprost, latanoprost and travoprost in the treatment of primary open angle glaucoma. Study arms of timolol in trials including the above mentioned lipid class drugs were also included. METHODS: MEDLINE and EMBASE were searched for randomized clinical trials including one or more of the lipid class drugs bimatoprost, latanoprost and travoprost. The study results were pooled, and the simple, weighted IOP-lowering efficacy was compared among the lipid class drugs and timolol, where data were available. Efficacy parameters were reviewed, including mean reduction of IOP and percentage of patients achieving different levels of IOP. RESULTS: 161 articles were identified of which 42 were included in the analysis. A total of 9295 patients participated in the included trials. Based on all studies, timolol on average had a weighted mean IOP reduction of 22.2%, while latanoprost, travoprost and bimatoprost had a weighted mean IOP reduction of 26.7%, 28.7% and 30.3%, respectively. Analysis of target achievement to various IOP levels shows that bimatoprost seems more efficacious than latanoprost. The direct comparisons (head-to-head studies) also show that bimatoprost is the most efficacious treatment, however it is not conclusive whether latanoprost or travoprost is better in reducing IOP. CONCLUSIONS: This review shows that bimatoprost seems to be the most efficacious treatment in lowering IOP. Head-to-head studies confirm this. SN - 0300-7995 UR - https://www.unboundmedicine.com/medline/citation/16307709/Analytic_review_of_bimatoprost_latanoprost_and_travoprost_in_primary_open_angle_glaucoma_ L2 - http://www.tandfonline.com/doi/full/10.1185/030079905X65600 DB - PRIME DP - Unbound Medicine ER -